Sign In

Antiretroviral Therapy.

HIV Question Bank

Switching or Simplifying Antiretroviral TherapyQuestion 8/10

Questions in Topic

A 32-year-old cisgender woman has been taking dolutegravir plus tenofovir alafenamide-emtricitabine for about 2 years. Two months after starting this regimen, she had suppressed HIV RNA levels and she has maintained suppressed HIV RNA levels since then. A baseline HIV drug resistance genotype showed an M184V mutation but no other mutations. In the past 3 months, she has developed some esophageal problems and is very interested in taking long-acting injectable cabotegravir and rilpivirine injections instead of daily pills.

Which one of the following statements is TRUE regarding the use of long-acting injectable cabotegravir and rilpivirine?

Figure 1. Monthly Dosing Schedule of Injectable Cabotegravir and Rilpivirine, with Optional Oral Lead-In
Illustration: David H. Spach, MD
Figure 2. Every 2-Month Dosing Schedule of Injectable Cabotegravir and Rilpivirine, with Optional Oral Lead-In
Illustration: David H. Spach, MD
Prev  Skip

Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 21st, 2023

Steps to Acquire CE for this Question Bank Topic:

1

Answer

Answer all questions
2

Score 80%+

Answer correctly
3

Claim CE

Choose CNE or CME
4

Give Feedback

Complete survey
5

Print Certificate

Obtain proof of CE

This question requires improvement because:


Comment further on how to improve this question or summary:



Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.